Matuguina, Mark John .

HRN: 24-79-98  Sex: Male

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
04/11/2024
CO-AMOXICLAV 457MG/5ML, 70ML SUSPENSION (BOT)
04/11/2024
04/18/2024
PO
6ml
Q8h
Laceration
Waiting Final Action 

Indication:  Empiric    Type of Infection:  Urinary TractSkin & Soft Tissue    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: